Altimmune (ALT) Projected to Release Quarterly Earnings on Thursday

Key Points

• Altimmune is expected to report Q3 2026 results before market open on November 5. Analysts project a loss of $0.14 per share and no revenue, with the earnings call scheduled for 8:30 a.m. ET.
• The company previously reported a $0.12 per-share loss, beating estimates of a $0.14 loss. Analysts expect full-year and next-year losses of $0.58 and $0.54 per share, respectively.
• Altimmune shares opened at $2.10, near their 52-week low of $2.00, while analysts maintain a consensus “Moderate Buy” rating and an average price target of $14.33.

Altimmune (NASDAQ:ALT - Get Free Report) is anticipated to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.14) per share and revenue of $0.00 million for the quarter. Interested persons can check the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. On average, analysts expect Altimmune to post ($0.58) EPS for the current fiscal year and ($0.54) EPS for the next fiscal year.

Altimmune Price Performance

NASDAQ ALT opened at $2.10 on Thursday. The company has a current ratio of 26.78, a quick ratio of 26.78 and a debt-to-equity ratio of 0.07. The company has a 50-day moving average price of $2.86 and a two-hundred day moving average price of $3.31. The stock has a market cap of $408.49 million, a price-to-earnings ratio of -2.69 and a beta of 0.06. Altimmune has a 52 week low of $2.00 and a 52 week high of $6.44.

Analyst Ratings Changes

A number of brokerages recently weighed in on ALT. Weiss Ratings restated a "sell (d-)" rating on shares of Altimmune in a research note on Monday, September 21st. HC Wainwright reiterated a "buy" rating on shares of Altimmune in a research report on Tuesday, July 28th. Finally, Evercore reiterated an "outperform" rating on shares of Altimmune in a research report on Wednesday, September 23rd. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $14.33.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for obesity and liver diseases. The company's research programs are designed to address metabolic and inflammatory conditions with significant unmet medical needs.

Altimmune's lead product candidate is pemvidutide, an investigational dual GLP-1 and glucagon receptor agonist being evaluated for chronic weight management and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.